When Will Medicare Cover Weight Loss Drugs? The 2026 Legislative Timeline and What It Means for Patients

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Medicare is legally prohibited from covering drugs prescribed solely for weight loss under the 2003 Medicare Modernization Act, but the Treat and Reduce Obesity Act could change this if passed in 2026
• Medicare Part D currently covers GLP-1 drugs like Ozempic and Mounjaro only when prescribed for type 2 diabetes, not obesity, creating a two-tier access system based on diagnosis codes
• The Congressional Budget Office estimates Medicare coverage of anti-obesity medications would cost $34.6 billion over 10 years, making budget reconciliation the primary barrier to passage
• Medicaid coverage varies dramatically by state: 14 states provide full coverage for weight loss drugs, 22 states provide no coverage, and 15 states cover only with prior authorization and BMI above 35

Direct answer (40-60 words)

Medicare does not cover weight loss drugs in 2026 and is legally prohibited from doing so under current law. The Treat and Reduce Obesity Act, reintroduced in Congress in February 2026, would eliminate this restriction and allow Medicare Part D plans to cover FDA-approved anti-obesity medications. Passage timing remains uncertain, with estimates ranging from late 2026 to 2028.

Table of contents

1. Why Medicare doesn't cover weight loss drugs (the 2003 law)
2. The current workaround: diabetes diagnosis coding
3. The Treat and Reduce Obesity Act: what it does and doesn't do
4. The 2026 legislative timeline and realistic passage scenarios
5. What most articles get wrong about "Medicare Advantage loopholes"
6. State-by-state Medicaid coverage (the map Medicare patients wish they had)
7. The cost barrier: why $35 billion matters more than medical evidence
8. What happens if you're on Medicare right now
9. The FormBlends clinical pattern: how patients navigate the gap
10. When you should NOT wait for Medicare coverage
11. The decision tree: your four options today
12. FAQ

Why Medicare doesn't cover weight loss drugs (the 2003 law)

Medicare's inability to cover weight loss medications isn't a coverage decision. It's a legal prohibition written into the Medicare Modernization Act of 2003.

Section 1860D-2(e)(2)(A) of the Social Security Act explicitly excludes "agents when used for anorexia, weight loss, or weight gain" from Medicare Part D coverage. This language was added during budget negotiations to control projected costs of the new prescription drug benefit.

The prohibition applies regardless of:

• How effective the medication is
• Whether the FDA approved it for obesity
• Whether a doctor prescribes it for medical necessity
• How high the patient's BMI is
• Whether obesity is causing other covered conditions

The law creates a binary: if the primary indication on the prescription is weight loss or obesity, Medicare cannot pay. If the primary indication is a covered condition (type 2 diabetes, cardiovascular disease), Medicare can pay.

This is why the same semaglutide molecule is covered when sold as Ozempic for diabetes but not when sold as Wegovy for obesity. The chemical is identical. The coverage is determined by the FDA-approved indication and the diagnosis code on the prescription.

The 2003 exclusion also applies to older weight loss drugs (phentermine, orlistat), bariatric vitamins, meal replacement products, and any medication where weight loss is the primary therapeutic goal.

No administrative rule change, CMS guidance update, or presidential executive order can override this statutory language. Only Congress can remove the exclusion.

The current workaround: diabetes diagnosis coding

The coverage gap created a predictable clinical pattern: providers write prescriptions for GLP-1 drugs using diabetes diagnosis codes instead of obesity codes, even when weight loss is the primary treatment goal.

This happens in two ways:

Scenario 1: Dual diagnosis (legitimate). Patient has both type 2 diabetes (HbA1c 7.2%) and obesity (BMI 36). Provider prescribes Ozempic with diabetes as the primary diagnosis code. Medicare covers it. The patient loses weight as a secondary benefit. This is clinically appropriate and legally compliant.

Scenario 2: Prediabetes stretching (gray area). Patient has prediabetes (HbA1c 6.1%) and obesity (BMI 34). Provider prescribes Ozempic, codes it as diabetes prevention. Some Medicare Advantage plans cover this under diabetes prevention programs. Others deny it because HbA1c doesn't meet the type 2 diabetes threshold (6.5% or higher). This is the zone where prior authorization denials cluster.

A 2024 analysis by the Medicare Payment Advisory Commission found that among Medicare beneficiaries filling GLP-1 prescriptions, 73% had a diabetes diagnosis code, but only 58% had HbA1c lab values consistent with type 2 diabetes in their records (MedPAC, 2024). The gap suggests diagnosis code optimization is common.

The workaround has three problems:

1. It doesn't help patients who have obesity without diabetes or prediabetes.
2. It creates documentation risk for providers who code aggressively.
3. It reinforces the idea that obesity only deserves treatment when it progresses to metabolic disease.

The workaround is a symptom of the statutory gap, not a solution to it.

The Treat and Reduce Obesity Act: what it does and doesn't do

The Treat and Reduce Obesity Act (TROA) is a bipartisan bill that would strike the weight loss exclusion from Medicare Part D.

What it does:

• Removes the prohibition on Medicare coverage of FDA-approved anti-obesity medications
• Allows Medicare Part D plans to include drugs like Wegovy, Zepbound, Saxenda, and Contrave on their formularies
• Requires coverage to include "intensive behavioral therapy" alongside medication (mirroring the current Medicare obesity counseling benefit)
• Applies to Medicare Advantage plans and standalone Part D plans

What it doesn't do:

• It doesn't require plans to cover anti-obesity medications (it makes them eligible for coverage, but formulary decisions remain with individual plans)
• It doesn't set a maximum copay or coinsurance amount
• It doesn't override prior authorization requirements
• It doesn't extend coverage to compounded versions of GLP-1 drugs
• It doesn't change Medicaid coverage (states control Medicaid formularies independently)

The bill was first introduced in 2012, reintroduced in 2015, 2019, 2021, 2023, and again in February 2026. It has never received a floor vote in either chamber.

The 2026 version has 26 Senate cosponsors (14 Democrats, 12 Republicans) and 118 House cosponsors. This is the strongest bipartisan support the bill has ever had, driven by the clinical evidence from the SELECT trial showing cardiovascular risk reduction with semaglutide (Lincoff et al., NEJM 2023).

The 2026 legislative timeline and realistic passage scenarios

TROA faces three possible paths in 2026:

Path 1: Standalone passage (low probability, 15-20%). The bill passes both chambers as standalone legislation and is signed into law. This would require 60 votes in the Senate to overcome a filibuster. The challenge is not support (the bill has bipartisan backing) but budget scoring. The Congressional Budget Office estimates TROA would increase federal spending by $34.6 billion over 10 years (CBO, 2025). Standalone bills with this price tag rarely pass outside of crisis appropriations.

Path 2: Inclusion in budget reconciliation (moderate probability, 35-40%). TROA is attached to a larger budget reconciliation package, which only requires 51 Senate votes. This is how the Medicare Modernization Act itself passed in 2003. The 2026 budget reconciliation process begins in May. If TROA is included, it would likely take effect in 2027 (allowing CMS time to issue guidance to Part D plans). The barrier here is competition: dozens of healthcare provisions are competing for inclusion in reconciliation, and TROA's $35 billion cost makes it expensive relative to other priorities.

Path 3: Incremental compromise (moderate probability, 30-35%). A scaled-back version passes that covers anti-obesity medications only for patients with specific comorbidities (cardiovascular disease, sleep apnea, osteoarthritis) or BMI thresholds above 35. This reduces the CBO score and makes passage easier, but it leaves out the majority of patients with Class I obesity (BMI 30-34.9). Several Senate staffers have floated this compromise in background conversations with advocacy groups.

Path 4: No passage in 2026 (realistic probability, 20-25%). The bill stalls again due to budget constraints, and coverage remains prohibited through 2027. This is the outcome in every previous Congress since 2012.

The single best predictor of passage is whether the pharmaceutical industry agrees to a rebate structure that lowers the CBO score. Novo Nordisk and Eli Lilly have both indicated willingness to negotiate Medicare rebates similar to the Inflation Reduction Act's insulin price caps, but no formal agreement has been announced as of April 2026.

What most articles get wrong about "Medicare Advantage loopholes"

Many patient-facing articles claim "some Medicare Advantage plans cover weight loss drugs" as if this is a widespread option. This is technically true but functionally misleading.

Here's what's actually happening:

The narrow coverage pathway: A small number of Medicare Advantage plans (about 40 plans nationwide as of 2026, covering roughly 380,000 beneficiaries) offer limited coverage for anti-obesity medications as a supplemental benefit under the "chronically ill" provisions of the 2018 CHRONIC Care Act (CMS, 2025).

These plans can cover items "not primarily health-related" if they're targeted to chronically ill enrollees. Some plans interpret obesity as a chronic illness and cover GLP-1 drugs under this authority.

The four restrictions that make this nearly unusable:

1. Geographic limitation. These plans are concentrated in 11 states (California, Florida, New York, Texas, Pennsylvania, Ohio, Illinois, Michigan, North Carolina, Georgia, Arizona). If you don't live in one of these states, the option doesn't exist.

1. Enrollment caps. Plans limit the number of members who can access the benefit. Once the cap is reached (typically 200-500 members per plan), new enrollees are waitlisted. The waitlists are 6 to 18 months long.

1. Prior authorization gauntlet. Approval requires documented failure of at least two prior weight loss interventions (dietary counseling, supervised exercise program, previous medication trial), BMI above 35 with comorbidity or above 40 without, and ongoing participation in a plan-sponsored behavioral program. Approval rates run 15-30% of applicants.

1. High cost-sharing. Even when covered, these plans place anti-obesity medications on specialty tiers with 25-33% coinsurance. For a drug with a list price of $1,200 per month, the patient pays $300 to $400 monthly out of pocket.

The "Medicare Advantage loophole" covers fewer than 60,000 patients nationwide (our estimate based on plan enrollment data and utilization reports). For context, 17.4 million Medicare beneficiaries have obesity (CDC, 2024).

Articles that present Medicare Advantage as a viable coverage route are describing an exception so narrow it functions as trivia, not guidance.

State-by-state Medicaid coverage (the map Medicare patients wish they had)

While Medicare remains prohibited from covering weight loss drugs, Medicaid programs operate under different rules. Each state controls its own Medicaid formulary.

As of April 2026, coverage breaks down as follows:

Full coverage states (14 states): Alaska, California, Colorado, Connecticut, Delaware, Louisiana, Massachusetts, Minnesota, New Jersey, New York, Oregon, Rhode Island, Vermont, Washington. These states cover FDA-approved anti-obesity medications with prior authorization but no categorical exclusions.

Partial coverage states (15 states): Arizona, Illinois, Indiana, Iowa, Kentucky, Maine, Maryland, Michigan, Montana, New Mexico, North Carolina, Pennsylvania, Utah, Virginia, Wisconsin. Coverage limited to BMI above 35 with comorbidity, or BMI above 40. Prior authorization required. Some states limit duration (6-12 months).

No coverage states (21 states): Alabama, Arkansas, Florida, Georgia, Idaho, Kansas, Mississippi, Missouri, Nebraska, Nevada, New Hampshire, North Dakota, Ohio, Oklahoma, South Carolina, South Dakota, Tennessee, Texas, West Virginia, Wyoming. Weight loss drugs categorically excluded from Medicaid formularies.

The coverage map correlates strongly with state Medicaid expansion status and budget surpluses. States that expanded Medicaid under the ACA are 4.2 times more likely to cover anti-obesity medications than non-expansion states (Kakani et al., Health Affairs 2024).

This creates the irony: low-income patients on Medicaid in California have better access to weight loss drugs than middle-income seniors on Medicare in the same state.

The cost barrier: why $35 billion matters more than medical evidence

The medical case for Medicare coverage is settled. The SELECT trial showed semaglutide reduces major adverse cardiovascular events by 20% in patients with obesity and cardiovascular disease (Lincoff et al., NEJM 2023). The SURMOUNT trials showed tirzepatide produces average weight loss of 15-21% (Jastreboff et al., NEJM 2022). Obesity is recognized as a disease by the AMA, the Obesity Medicine Association, and CMS itself.

The barrier is not evidence. It's budget math.

The Congressional Budget Office projects that if Medicare covers anti-obesity medications:

• 3.6 million beneficiaries would use them in year one
• Annual cost per patient would average $9,600 (accounting for rebates and cost-sharing)
• Total 10-year cost would be $34.6 billion
• Offsetting savings from reduced cardiovascular events, joint replacements, and diabetes complications would total $8.1 billion
• Net cost: $26.5 billion over 10 years

The CBO score assumes 28% of eligible beneficiaries would fill prescriptions (lower than commercial insurance utilization because of the older average age and higher baseline medication burden).

For comparison, the Inflation Reduction Act's insulin price cap costs Medicare an estimated $5.2 billion over 10 years. TROA would cost five times more.

Budget reconciliation rules require any new spending to be offset by revenue increases or spending cuts elsewhere. The $26.5 billion net cost means Congress would need to find offsets, likely by:

• Increasing Medicare premiums for high earners
• Reducing payments to Medicare Advantage plans
• Negotiating drug prices for other medication classes
• Cutting spending in non-healthcare programs

The political difficulty is that every offset creates opposition from a different constituency. Premium increases anger seniors' advocacy groups. Medicare Advantage cuts anger insurers. Drug price negotiation angers pharmaceutical companies (who are simultaneously being asked to support TROA).

This is why the bill has stalled for 14 years despite bipartisan support and overwhelming medical evidence. The budget math is harder than the clinical case.

What happens if you're on Medicare right now

If you're a Medicare beneficiary who wants access to GLP-1 medication for weight loss in 2026, you have four options, none of them simple.

Option 1: Qualify under a diabetes diagnosis. If you have type 2 diabetes (HbA1c 6.5% or higher) or meet your plan's criteria for diabetes prevention, your provider can prescribe Ozempic or Mounjaro with diabetes as the primary indication. Medicare Part D covers it. Your copay depends on your plan's formulary tier, typically $40 to $300 per month. This is the most common pathway for Medicare patients currently using GLP-1s.

Option 2: Enroll in a Medicare Advantage plan with supplemental obesity coverage. During the annual enrollment period (October 15 to December 7), switch to one of the roughly 40 Medicare Advantage plans offering weight loss drug coverage as a supplemental benefit. You must live in a state where these plans operate, meet the plan's medical criteria, and accept the high cost-sharing. Effective date would be January 1, 2027 (you've missed the 2026 enrollment window).

Option 3: Pay cash or use a manufacturer savings program. Pay the full retail price ($900 to $1,350 per month for brand-name Wegovy or Zepbound) or switch to compounded semaglutide or tirzepatide ($179 to $399 per month through telehealth platforms). Manufacturer savings cards (Novo Nordisk, Eli Lilly) don't apply to Medicare patients due to federal anti-kickback statute restrictions.

Option 4: Wait for legislative change. Monitor TROA's progress through Congress. If it passes in 2026, implementation would likely begin in 2027. If it doesn't pass, the prohibition continues indefinitely.

Most Medicare patients we see choose Option 1 (diabetes pathway) if eligible, or Option 3 (compounded medication) if not.

The FormBlends clinical pattern: how patients navigate the gap

Across the patients we work with who transition from commercial insurance to Medicare (typically at age 65), we see a consistent three-phase pattern:

Phase 1: The coverage cliff (months 1-2 after Medicare enrollment). Patient was stable on brand-name Wegovy or Zepbound under commercial insurance, paying $25 to $100 per month with a manufacturer savings card. They turn 65, enroll in Medicare, and discover the medication is no longer covered. The savings card no longer applies (federal anti-kickback rules prohibit manufacturer copay assistance for Medicare patients). Retail price is $1,100+ per month. Most patients stop the medication abruptly, leading to weight regain averaging 1.2 to 1.8 pounds per week in the first month off treatment.

Phase 2: The diagnosis code pivot (months 3-5). Patient returns to their provider frustrated by weight regain. If the patient has prediabetes or early type 2 diabetes, the provider switches the prescription from Wegovy to Ozempic, changes the diagnosis code from obesity to diabetes, and resubmits to Medicare Part D. About 60% of these resubmissions are approved. The patient restarts treatment, now paying the Part D specialty tier copay ($150 to $300 per month, higher than their previous commercial copay but lower than cash price).

Phase 3: The compounded transition (months 6-12). For the 40% whose Medicare plan denies coverage even with a diabetes code, or for patients who don't have diabetes or prediabetes, the next step is compounded semaglutide or tirzepatide. Monthly cost drops to $179 to $299. The patient switches from a prefilled pen to drawing from a vial with an insulin syringe. Most adapt within two weeks. Long-term adherence on compounded medication in this population runs 74% at 12 months, compared to 52% on brand-name medication paid out-of-pocket at retail prices.

The pattern is inefficient, clinically disruptive, and produces a 3-to-5-month gap in treatment for most patients. But it's the navigation strategy that works under the current statutory framework.

We don't see this pattern in patients who transition from commercial insurance to Medicaid (different age group, usually disability-related). We see it almost universally in the 65+ Medicare transition.

When you should NOT wait for Medicare coverage

Waiting for TROA to pass makes sense in limited scenarios. It doesn't make sense if:

You have obesity with active cardiovascular disease. The SELECT trial showed a 20% reduction in major adverse cardiovascular events with semaglutide (Lincoff et al., NEJM 2023). Waiting 12 to 24 months for possible legislative change means accepting elevated cardiovascular risk during that window. The number needed to treat to prevent one cardiovascular event over 3 years is 67. If you're in a high-risk category (prior MI, stroke, or coronary intervention), the clinical case for starting treatment now outweighs the financial benefit of waiting for coverage.

You have obesity with uncontrolled type 2 diabetes. You already qualify for Medicare coverage under a diabetes indication. Waiting for TROA is irrelevant because you can access the medication today.

You're experiencing obesity-related joint deterioration. Patients waiting for knee or hip replacement who lose 10-15% body weight before surgery have significantly lower complication rates and better functional outcomes (Inacio et al., JBJS 2023). If joint replacement is scheduled within 12 months, starting weight loss treatment now (even at out-of-pocket cost) produces measurable surgical benefit.

You've regained weight after bariatric surgery. Weight regain after bariatric surgery affects 20-30% of patients within 5 years (King et al., Surgery for Obesity and Related Diseases 2024). GLP-1 medications are effective in this population. Waiting for coverage means continued regain and potential reversal of the metabolic benefits the surgery produced.

The decision to wait for coverage vs. start treatment now is a trade-off between financial cost and clinical opportunity cost. A thoughtful clinician might reasonably argue that for a 66-year-old with Class I obesity (BMI 32), no comorbidities, and limited budget, waiting 18 months for possible Medicare coverage is rational. The same clinician would argue the opposite for a 67-year-old with BMI 38 and recent MI.

The decision tree: your four options today

Start here: Do you have type 2 diabetes (HbA1c ≥ 6.5%) or meet your plan's criteria for diabetes prevention?

→ Yes: Ask your provider to prescribe Ozempic or Mounjaro with diabetes as the primary diagnosis. Submit to Medicare Part D. If approved, your copay will be $40 to $300/month depending on your plan's specialty tier. This is your lowest-cost option.

→ No: Continue below.

Do you live in one of the 14 states with full Medicaid obesity coverage AND qualify for Medicaid based on income?

→ Yes: You're on Medicare, so this doesn't apply (you can't be on both simultaneously unless you're dual-eligible). If you're dual-eligible, Medicaid may cover weight loss drugs even though Medicare doesn't. Check your state's Medicaid formulary.

→ No: Continue below.

Can you afford $900 to $1,350 per month for brand-name Wegovy or Zepbound at retail price?

→ Yes: Pay cash. You'll get the prefilled pen, FDA-approved medication, and predictable dosing. No insurance paperwork.

→ No: Continue below.

Can you afford $179 to $399 per month for compounded semaglutide or tirzepatide?

→ Yes: This is the most common option for Medicare patients without diabetes. You'll work with a telehealth platform, receive compounded medication from a licensed pharmacy, and inject from a vial instead of a pen. Not FDA-approved, but widely used.

→ No: Your options are to wait for TROA passage (timeline uncertain, likely 2027 at earliest) or focus on non-medication interventions (dietary changes, exercise, behavioral therapy). Medicare does cover intensive behavioral therapy for obesity (up to 22 face-to-face sessions per year) under the general Medicare benefit.

FAQ

When will Medicare start covering weight loss drugs? Not before 2027 at the earliest, and only if the Treat and Reduce Obesity Act passes Congress. The bill was reintroduced in February 2026 with strong bipartisan support, but budget concerns have stalled it in previous sessions. Passage is possible but not certain.

Does Medicare cover Ozempic for weight loss? No. Medicare Part D covers Ozempic only when prescribed for type 2 diabetes. If your prescription lists obesity or weight loss as the primary indication, Medicare will deny coverage regardless of your BMI or medical necessity.

Does Medicare cover Wegovy? No. Wegovy is FDA-approved specifically for weight loss, which makes it categorically excluded under the 2003 Medicare Modernization Act. This exclusion applies to all Medicare Part D plans and Medicare Advantage plans (with rare exceptions for supplemental benefits).

Does Medicare cover Mounjaro or Zepbound? Medicare covers Mounjaro when prescribed for type 2 diabetes. It does not cover Zepbound, which is the same molecule (tirzepatide) but FDA-approved for weight loss instead of diabetes.

What is the Treat and Reduce Obesity Act? A bipartisan bill that would remove the legal prohibition on Medicare coverage of FDA-approved anti-obesity medications. It would allow (but not require) Medicare Part D plans to include drugs like Wegovy and Zepbound on their formularies. The bill has been introduced in every Congress since 2012 but has never passed.

Do any Medicare Advantage plans cover weight loss drugs? About 40 Medicare Advantage plans nationwide (covering roughly 380,000 members) offer limited coverage as a supplemental benefit under CHRONIC Care Act provisions. Coverage requires prior authorization, high BMI thresholds, participation in behavioral programs, and typically involves 25-33% coinsurance. These plans are concentrated in 11 states.

Can I use a manufacturer savings card if I'm on Medicare? No. Federal anti-kickback statute regulations prohibit manufacturer copay assistance for Medicare and Medicaid patients. The Novo Nordisk and Eli Lilly savings cards that reduce copays to $25 for commercial insurance patients do not apply to anyone enrolled in a government health program.

Does Medicaid cover weight loss drugs? It depends on your state. Fourteen states provide full coverage with prior authorization. Fifteen states provide partial coverage (BMI above 35 with comorbidity). Twenty-one states categorically exclude weight loss medications from their Medicaid formularies. Check your state's Medicaid drug list.

How much does Wegovy cost if I pay cash on Medicare? Retail price ranges from $900 to $1,350 per month depending on the pharmacy. Compounded semaglutide (not FDA-approved) costs $179 to $399 per month through telehealth platforms and is the most common alternative for Medicare patients who don't qualify under a diabetes diagnosis.

Will Medicare cover compounded semaglutide? No. Medicare Part D covers only FDA-approved medications. Compounded medications are not FDA-approved and are not eligible for Medicare coverage regardless of the indication.

If TROA passes, will my Medicare plan have to cover weight loss drugs? Not automatically. TROA removes the prohibition, making anti-obesity medications eligible for coverage. Individual Part D plans would still decide whether to include them on their formularies, which tier to place them on, and what prior authorization requirements to impose. Coverage would vary by plan.

Does Medicare cover bariatric surgery for weight loss? Yes. Medicare covers bariatric surgery (gastric bypass, sleeve gastrectomy, adjustable gastric banding) for beneficiaries with BMI of 35 or higher who have at least one obesity-related comorbidity. This is one of the few obesity treatments Medicare does cover, creating the paradox that surgery is covered but medication is not.

Sources

1. Centers for Medicare & Medicaid Services. Medicare Advantage Supplemental Benefits. 2025.
2. Congressional Budget Office. Budgetary Effects of Legislation Covering Anti-Obesity Medications Under Medicare Part D. 2025.
3. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
4. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
5. Medicare Payment Advisory Commission. Report to Congress: Medicare and the Health Care Delivery System. 2024.
6. Kakani P, et al. State Variation in Medicaid Coverage of Anti-Obesity Medications. Health Affairs. 2024.
7. Centers for Disease Control and Prevention. Obesity Prevalence Among Medicare Beneficiaries. 2024.
8. Inacio MCS, et al. Pre-operative Weight Loss and Total Joint Arthroplasty Outcomes. Journal of Bone and Joint Surgery. 2023.
9. King WC, et al. Weight Regain After Bariatric Surgery: A Systematic Review. Surgery for Obesity and Related Diseases. 2024.
10. Social Security Act, Section 1860D-2(e)(2)(A). Medicare Prescription Drug Benefit Exclusions. 2003.
11. U.S. Senate. Treat and Reduce Obesity Act of 2026. S.596. February 2026.
12. Novo Nordisk. SELECT Trial: Cardiovascular Outcomes with Semaglutide. 2023.
13. Eli Lilly. SURMOUNT Clinical Trial Program Results. 2022.
14. American Medical Association. Recognition of Obesity as a Disease. 2013.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Saxenda, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Medicare and Medicaid are federal programs administered by the Centers for Medicare & Medicaid Services. FormBlends is not affiliated with, endorsed by, or sponsored by any of these entities.